{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:16:50Z","timestamp":1754144210438,"version":"3.41.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.rmed.2025.108070","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T11:11:02Z","timestamp":1743333062000},"page":"108070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pulse corticosteroid therapy in interstitial lung disease-associated with anti-aminoacyl-tRNA synthetase antibodies: Comparable efficacy with potential for reduced adverse events"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-087X","authenticated-orcid":false,"given":"Shota","family":"Kaburaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9181","authenticated-orcid":false,"given":"Akihiko","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namiko","family":"Taniuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-7030","authenticated-orcid":false,"given":"Yosuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2025.108070_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.rmed.2025.108070_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"Won","year":"2007","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib3","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.rmed.2025.108070_bib4","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2025.108070_bib5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Care Res."},{"issue":"11","key":"10.1016\/j.rmed.2025.108070_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/resp.13365","article-title":"Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus","volume":"23","author":"Yamano","year":"2018","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rmed.2025.108070_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108070_bib9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rmed.2025.108070_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/thorax.56.4.279","article-title":"Adverse effects of oral corticosteroids in relation to dose in patients with lung disease","volume":"56","author":"Walsh","year":"2001","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.rmed.2025.108070_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108070_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002076","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir. Res."},{"issue":"Suppl 134","key":"10.1016\/j.rmed.2025.108070_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108070_bib15","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.rmed.2025.108070_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"issue":"49","key":"10.1016\/j.rmed.2025.108070_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013542","article-title":"Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: a retrospective cohort study","volume":"97","author":"Yamaguchi","year":"2018","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.rmed.2025.108070_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir. Investig."},{"issue":"6","key":"10.1016\/j.rmed.2025.108070_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1148\/radiol.2471070369","article-title":"Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time","volume":"247","author":"Silva","year":"2008","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.rmed.2025.108070_bib21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.rmed.2009.05.001","article-title":"Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia","volume":"103","author":"Fischer","year":"2009","journal-title":"Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108070_bib22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and Progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.rmed.2025.108070_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0002-9343(00)00711-7","article-title":"Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival","volume":"110","author":"Flaherty","year":"2001","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib25","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1038\/s41598-021-85539-1","article-title":"Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.rmed.2025.108070_bib26","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s10067-016-3357-z","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Zamora-Legoff","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2025.108070_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108070_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jmv.27351","article-title":"Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit","volume":"94","author":"Yaqoob","year":"2022","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.rmed.2025.108070_bib31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/rheumatology\/key420","article-title":"Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease","volume":"58","author":"Takanashi","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rmed.2025.108070_bib32","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/crj.12797","article-title":"Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis","volume":"12","author":"Isoda","year":"2018","journal-title":"Clin. Res. J"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:04:29Z","timestamp":1752573869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0954611125001325"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108070","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulse corticosteroid therapy in interstitial lung disease-associated with anti-aminoacyl-tRNA synthetase antibodies: Comparable efficacy with potential for reduced adverse events","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108070"}}